FIELD: chemistry.
SUBSTANCE: invention relates to compounds or their pharmaceutically acceptable salts, where compound has formula 
1-a, in which R1 and R3 are absent, m represents integer number from 1 to 2, n represents integer number from 1 to 3, A represents 
, B represents 
or 
, where X2 represents O or S, R4a is absent, R4b is selected from the group, consisting of: 
, 
, 
, 
, 
and 
; Rk is selected from C1-6alkyl and C1-6halogenalkyl, L and E are such as given in i.1 of the invention formula; or compound is such as given in b) of i.1 of the invention formula. Invention also relates to pharmaceutical composition, which contains said compounds.
EFFECT: compounds by i1, possessing inhibiting activity with respect to anti-apoptosis protein Bcl-XL.
27 cl, 6 dwg, 2 tbl, 126 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS AND METHODS FOR USING | 2009 |
|
RU2561109C2 |
| AGENTS CAUSING APOPTOSIS AND INTENDED FOR TREATING CANCER, IMMUNE AND AUTOIMMUNE DISEASES | 2012 |
|
RU2594282C2 |
| 8-CARBAMOYL-2-(2,3-DI-SUBSTITUTED PYRID-6-YL)-1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS-INDUCING AGENTS FOR CANCER TREATMENT | 2012 |
|
RU2625315C2 |
| ANTIBODIES TO B7-H3 AND CONJUGATES OF ANTIBODY AND DRUG | 2017 |
|
RU2764651C2 |
| PYRIDINES SUBSTITUTED WITH HETEROARYL AND APPLICATION METHODS | 2017 |
|
RU2756743C2 |
| GLYCOLATOXIDASE INHIBITORS FOR THE TREATMENT OF DISEASES | 2018 |
|
RU2805308C2 |
| BROMDOMAIN INHIBITORS | 2012 |
|
RU2647592C2 |
| 5-SUBSTITUTED INDAZOLE AS KINASE INHIBITORS | 2008 |
|
RU2487873C2 |
| TYPE 1 DIACYLGLYCEROL O-ACYLTRANSFERASE ENZYME INHIBITORS | 2008 |
|
RU2497816C2 |
| PRIMARY CARBOXAMIDES AS BTK INHIBITORS | 2014 |
|
RU2708395C2 |
